レプトスピラ症の世界市場

レプトスピラ症の世界市場は2030年までに6億5,050万米ドルに達する見込み

2024年に5億1,010万米ドルと推定されるレプトスピラ症の世界市場は、2030年には6億5,050万米ドルに達し、分析期間2024-2030年のCAGRは4.1%で成長すると予測されます。本レポートで分析したセグメントの1つである完全血球計数検査は、CAGR 3.7%を記録し、分析期間終了時には1億9,320万米ドルに達すると予測されます。クレアチンキナーゼ検査分野の成長率は、分析期間中CAGR 4.1％と推定されます。

米国市場は1億3,900万米ドルと推定、中国はCAGR7.5％で成長予測

米国のレプトスピラ症市場は、2024年に1億3,900万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに1億3,200万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは7.5%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.7%と3.2%と予測されています。欧州では、ドイツがCAGR 2.4%で成長すると予測されています。

世界のレプトスピラ症市場- 主要動向と促進要因のまとめ

レプトスピラ症が世界の公衆衛生上の懸念事項として浮上しているのはなぜか？

レプトスピラ症は、Leptospira種によって引き起こされる細菌性人獣共通感染症であり、熱帯地域と温帯地域の両方で発生が増加していることから、再注目を集めています。この病気は、感染した動物の尿や汚染された水や土壌に直接触れることで感染するため、衛生状態が悪く、洪水やげっ歯類の生息数が多い地域で特に流行しています。気候変動により、ハリケーンや豪雨などの異常気象が増加するにつれ、都市部や都市近郊の水系感染の多い地域では、レプトスピラ症の発症率が上昇しています。このような動きは、かつては農村部や職業病と見なされていたものを、より広範な公衆衛生の課題へと変えています。

中低所得国の多くでは、デング熱やインフルエンザなどのウイルス感染に似た非特異的な症状のため、レプトスピラ症の診断が遅れています。しかし、認知度の向上と診断ツールの改善（特にポイントオブケア分子検査）により、早期発見・早期介入が可能となっています。公衆衛生機関は現在、特に東南アジア、ラテンアメリカ、サハラ以南のアフリカにおいて、レプトスピラ症サーベイランスをより広範な感染症モニタリングシステムに統合しています。このような取り組みにより、アウトブレイクの地図化、季節的パターンの把握、標的を絞った管理戦略のためのハイリスク集団の特定が可能となっています。

診断、治療、予防戦略はどのように進化しているのか？

診断法の進歩は、レプトスピラ症の臨床管理を大幅に改善しています。顕微鏡凝集試験（MAT）のような伝統的な検査は、PCR、ELISA、ラテラルフローアッセイなど、より迅速で感度の高い技術によって補完されつつあります。これらの技術革新は、感染初期に最も有効なドキシサイクリンやペニシリンなどの抗生物質による早期介入を可能にしています。特に肝機能障害や腎機能障害を伴う重症例に対しては、併用療法や支持療法的アプローチが改良されつつあります。

予防面では、ヒト用ワクチンと動物用ワクチンが新たに開発されています。既存の動物用ワクチンは、より広い血清群をカバーできるように改良されており、ヒト用ワクチン候補は、交差防御免疫を提供することを目的とした新しい製剤で開発中です。流行地域では、総合的なベクターコントロール戦略、衛生環境の改善、げっ歯類の個体数管理も優先されています。さらに、官民パートナーシップとワンヘルスアプローチ（ヒト、動物、環境の健康を結びつける）の台頭により、長期的な予防と対応計画が強化されつつあります。

サーベイランス、アウトブレイク管理、公共政策における新たな動向とは？

COVID-19のパンデミックは、公衆衛生インフラへの投資を加速させ、それは現在、レプトスピラ症を含む他の感染症の追跡にも活用されています。デジタル監視システム、モバイル報告プラットフォーム、GISマッピングツールは、リアルタイムで発生を追跡し、気象パターンや社会環境要因に基づいて将来のホットスポットを予測するために使用されています。各国政府は、特に災害後の集団発生が頻発する洪水多発地域において、災害対応の枠組みにレプトスピラ症リスクを組み込んでいます。

WHOやCDCのような国際機関も、資金援助、研修、調整されたガイドラインを通じて、レプトスピラ症の調査と対策への支援を強化しています。特に家畜や野生動物が疾病感染に大きな役割を果たしている国々では、保健省、農務省、環境省の間でワンヘルス（One Health）連携を推進する政策枠組みが浸透しつつあります。このような動向により、世界保健の優先課題としてレプトスピラ症を管理するための、より体系的で統合的なアプローチが構築されつつあります。

世界のレプトスピラ症診断・治療市場の成長の原動力は？

レプトスピラ症市場の成長は、気候による疾病の拡大、診断法の改善、公衆衛生への投資の高まりなど、いくつかの要因によってもたらされます。主要な促進要因は、都市部における洪水関連のアウトブレイクの増加であり、迅速検査、早期治療プロトコル、抗生物質の備蓄に対する強い需要を生み出しています。新興国におけるペットの飼育や畜産の増加も、潜在的な感染源を拡大しており、動物用診断薬とワクチンの市場をさらに押し上げています。

政府の支援による保健衛生への取り組みと、世界の保健衛生組織からの資金提供により、十分なサービスを受けていない地域での診断キットや監視技術へのアクセスが増加しています。組換えワクチン開発とバイオインフォマティクスに基づく血清型追跡の進歩は研究投資を誘致し、製薬会社は再利用薬と免疫調整療法を模索しています。最後に、パンデミック対策の枠組みにレプトスピラ症モニタリングが統合されたことで、ヒトと獣医の両方の健康エコシステムにおける関連性が強化され、診断、治療、公衆衛生サービスの成長が加速しています。

セグメント

診断（全血球算定、クレアチンキナーゼ、肝酵素、尿検査、その他の診断）;投与経路（経口、非経口、静脈内）;販売チャネル（病院薬局、小売薬局、オンライン薬局）

調査対象企業の例（注目の43社）

• Anatolia Geneworks
• Bayer AG
• Boehringer Ingelheim GmbH
• Ceva Sante Animale
• Elanco Animal Health
• IDEXX Laboratories, Inc.
• Indian Immunologicals Ltd.
• International Vaccine Institute（IVI）
• Merck & Co., Inc.
• MSD Animal Health
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Serum Institute of India
• Shionogi & Co., Ltd.
• Takeda Pharmaceutical Company
• Vaxxinova International B.V.
• Virbac
• Zoetis Inc.
• Zydus Cadila

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Leptospirosis Market to Reach US$650.5 Million by 2030

The global market for Leptospirosis estimated at US$510.1 Million in the year 2024, is expected to reach US$650.5 Million by 2030, growing at a CAGR of 4.1% over the analysis period 2024-2030. Complete Blood Count Test, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$193.2 Million by the end of the analysis period. Growth in the Creatine Kinase Test segment is estimated at 4.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$139.0 Million While China is Forecast to Grow at 7.5% CAGR

The Leptospirosis market in the U.S. is estimated at US$139.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$132.0 Million by the year 2030 trailing a CAGR of 7.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 3.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.4% CAGR.

Global Leptospirosis Market - Key Trends & Drivers Summarized

Why Is Leptospirosis Emerging as a Global Public Health Concern?

Leptospirosis, a bacterial zoonotic disease caused by Leptospira species, is gaining renewed attention as outbreaks increase in both tropical and temperate regions. The disease is transmitted through direct contact with the urine of infected animals or contaminated water and soil, making it especially prevalent in areas with poor sanitation, flooding, and high rodent populations. As climate change leads to more extreme weather events, including hurricanes and heavy rainfall, the incidence of leptospirosis is rising in urban and peri-urban regions, where waterborne exposure is common. This dynamic has turned what was once seen as a rural or occupational disease into a broader public health challenge.

In many low- and middle-income countries, leptospirosis remains underdiagnosed due to its nonspecific symptoms, which mimic viral infections such as dengue and influenza. However, growing awareness and improved diagnostic tools-particularly point-of-care molecular tests-are facilitating earlier identification and intervention. Public health agencies are now integrating leptospirosis surveillance into broader infectious disease monitoring systems, particularly in Southeast Asia, Latin America, and sub-Saharan Africa. These efforts are helping to map outbreaks, understand seasonal patterns, and identify high-risk populations for targeted control strategies.

How Are Diagnostics, Therapeutics, and Preventive Strategies Evolving?

Advances in diagnostic methods are significantly improving the clinical management of leptospirosis. Traditional tests such as the microscopic agglutination test (MAT) are being supplemented by faster, more sensitive techniques including PCR, ELISA, and lateral flow assays. These innovations are enabling earlier intervention with antibiotics such as doxycycline and penicillin, which are most effective in the early phase of infection. Combination therapies and supportive care approaches are being refined, especially for severe cases involving liver or kidney dysfunction.

On the preventive front, human and veterinary vaccines are under renewed development. Existing animal vaccines are being improved to offer broader serovar coverage, while human vaccine candidates are in the pipeline with novel formulations aimed at providing cross-protective immunity. Integrated vector control strategies, sanitation improvements, and rodent population management are also being prioritized in endemic regions. Additionally, the rise of public-private partnerships and One Health approaches-linking human, animal, and environmental health-is enhancing long-term prevention and response planning.

What Are the Emerging Trends in Surveillance, Outbreak Management, and Public Policy?

The COVID-19 pandemic has accelerated investment in public health infrastructure, which is now being leveraged to track other infectious diseases, including leptospirosis. Digital surveillance systems, mobile reporting platforms, and GIS mapping tools are being used to track outbreaks in real time and forecast future hotspots based on weather patterns and socio-environmental factors. Governments are incorporating leptospirosis risk into disaster response frameworks, particularly in flood-prone regions where post-disaster outbreaks are frequent.

International agencies such as WHO and CDC are also enhancing support for leptospirosis research and control efforts through funding, training, and coordinated guidelines. Policy frameworks promoting One Health collaboration between ministries of health, agriculture, and environment are gaining traction, especially in countries where livestock and wildlife play a major role in disease transmission. These trends are creating a more structured and integrated approach to managing leptospirosis as a global health priority.

What Is Driving Growth in the Leptospirosis Diagnostics and Treatment Market Globally?

The growth in the leptospirosis market is driven by several factors including climate-induced disease spread, improved diagnostics, and heightened public health investment. A key driver is the increase in flood-related outbreaks in urban areas, creating strong demand for rapid testing, early treatment protocols, and stockpiling of antibiotics. Rising pet ownership and livestock farming in developing nations are also expanding the reservoir of potential infections, further boosting veterinary diagnostics and vaccine markets.

Government-backed health initiatives, coupled with donor funding from global health organizations, are increasing access to diagnostic kits and surveillance technologies in underserved regions. Advances in recombinant vaccine development and bioinformatics-based serovar tracking are attracting research investments, while pharma companies are exploring repurposed drugs and immune-modulating therapies. Lastly, the integration of leptospirosis monitoring into pandemic preparedness frameworks is reinforcing its relevance in both human and veterinary health ecosystems-fueling growth in diagnostics, treatment, and public health services.

SCOPE OF STUDY:

The report analyzes the Leptospirosis market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Diagnosis (Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis, Other Diagnosis); Administration Route (Oral, Parenteral, Intravenous); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

• Anatolia Geneworks
• Bayer AG
• Boehringer Ingelheim GmbH
• Ceva Sante Animale
• Elanco Animal Health
• IDEXX Laboratories, Inc.
• Indian Immunologicals Ltd.
• International Vaccine Institute (IVI)
• Merck & Co., Inc.
• MSD Animal Health
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Serum Institute of India
• Shionogi & Co., Ltd.
• Takeda Pharmaceutical Company
• Vaxxinova International B.V.
• Virbac
• Zoetis Inc.
• Zydus Cadila

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Leptospirosis - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Flooding and Urban Water Contamination Drives Demand for Leptospirosis Diagnostics and Vaccines
  • Expansion of Zoonotic Disease Surveillance Programs Strengthens Public Health Response to Leptospirosis Outbreaks
  • Increased Human-Wildlife Interface in Urban and Agricultural Zones Spurs Transmission Risk and Diagnostic Demand
  • Climate Change and Seasonal Rainfall Extremes Accelerate Geographic Spread of Leptospirosis in Vulnerable Regions
  • Growing Awareness of Leptospirosis in Veterinary and Livestock Sectors Supports Cross-Sector Disease Monitoring
  • Inclusion of Leptospirosis in Global Neglected Tropical Disease (NTD) Initiatives Expands Funding and Research Support
  • Government Vaccination Drives in Endemic Countries Propel Demand for Cost-Effective Leptospirosis Vaccines
  • Rising Travel to Tropical Regions and Adventure Tourism Increases Prophylactic Treatment Opportunities
  • Push for Rapid and Point-of-Care Testing Enhances Market Growth for Leptospira Detection Kits
  • Outbreaks in Flood-Affected Urban Slums Throw Spotlight on Infrastructure-Driven Health Vulnerabilities
  • Use of Serological and Molecular Diagnostics in Rural Clinics Expands Access to Early-Stage Leptospirosis Detection
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Leptospirosis Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Leptospirosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Leptospirosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Leptospirosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Complete Blood Count by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Complete Blood Count by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Complete Blood Count by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Creatine Kinase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Creatine Kinase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Creatine Kinase by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Liver Enzymes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Liver Enzymes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Liver Enzymes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Urinalysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Urinalysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Urinalysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Intravenous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Leptospirosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 38: USA Recent Past, Current & Future Analysis for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Leptospirosis by Diagnosis - Percentage Breakdown of Value Sales for Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis for the Years 2015, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Leptospirosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Leptospirosis by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Intravenous for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Leptospirosis by Diagnosis - Percentage Breakdown of Value Sales for Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis for the Years 2015, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Leptospirosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Leptospirosis by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Intravenous for the Years 2015, 2025 & 2030
• JAPAN
  • Leptospirosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Leptospirosis by Diagnosis - Percentage Breakdown of Value Sales for Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis for the Years 2015, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Leptospirosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Leptospirosis by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Intravenous for the Years 2015, 2025 & 2030
• CHINA
  • Leptospirosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 65: China Recent Past, Current & Future Analysis for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Leptospirosis by Diagnosis - Percentage Breakdown of Value Sales for Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis for the Years 2015, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Leptospirosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: China 15-Year Perspective for Leptospirosis by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Intravenous for the Years 2015, 2025 & 2030
• EUROPE
  • Leptospirosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Leptospirosis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Leptospirosis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Leptospirosis by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Leptospirosis by Diagnosis - Percentage Breakdown of Value Sales for Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis for the Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Leptospirosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Leptospirosis by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Intravenous for the Years 2015, 2025 & 2030
• FRANCE
  • Leptospirosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 86: France Recent Past, Current & Future Analysis for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for Leptospirosis by Diagnosis - Percentage Breakdown of Value Sales for Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis for the Years 2015, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Leptospirosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: France 15-Year Perspective for Leptospirosis by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Intravenous for the Years 2015, 2025 & 2030
• GERMANY
  • Leptospirosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for Leptospirosis by Diagnosis - Percentage Breakdown of Value Sales for Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis for the Years 2015, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Leptospirosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: Germany 15-Year Perspective for Leptospirosis by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Intravenous for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for Leptospirosis by Diagnosis - Percentage Breakdown of Value Sales for Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis for the Years 2015, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Leptospirosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: Italy 15-Year Perspective for Leptospirosis by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Intravenous for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Leptospirosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 113: UK Recent Past, Current & Future Analysis for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for Leptospirosis by Diagnosis - Percentage Breakdown of Value Sales for Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis for the Years 2015, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Leptospirosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: UK 15-Year Perspective for Leptospirosis by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Intravenous for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for Leptospirosis by Diagnosis - Percentage Breakdown of Value Sales for Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis for the Years 2015, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Leptospirosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: Spain 15-Year Perspective for Leptospirosis by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Intravenous for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for Leptospirosis by Diagnosis - Percentage Breakdown of Value Sales for Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis for the Years 2015, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Leptospirosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: Russia 15-Year Perspective for Leptospirosis by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Intravenous for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for Leptospirosis by Diagnosis - Percentage Breakdown of Value Sales for Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis for the Years 2015, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Leptospirosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 15-Year Perspective for Leptospirosis by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Intravenous for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Leptospirosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Leptospirosis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Leptospirosis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Leptospirosis by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Leptospirosis by Diagnosis - Percentage Breakdown of Value Sales for Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis for the Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Leptospirosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 15-Year Perspective for Leptospirosis by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Intravenous for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Leptospirosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for Leptospirosis by Diagnosis - Percentage Breakdown of Value Sales for Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis for the Years 2015, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Leptospirosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: Australia 15-Year Perspective for Leptospirosis by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Intravenous for the Years 2015, 2025 & 2030
• INDIA
  • Leptospirosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 170: India Recent Past, Current & Future Analysis for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for Leptospirosis by Diagnosis - Percentage Breakdown of Value Sales for Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis for the Years 2015, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Leptospirosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: India 15-Year Perspective for Leptospirosis by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Intravenous for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for Leptospirosis by Diagnosis - Percentage Breakdown of Value Sales for Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis for the Years 2015, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Leptospirosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: South Korea 15-Year Perspective for Leptospirosis by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Intravenous for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Leptospirosis by Diagnosis - Percentage Breakdown of Value Sales for Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Leptospirosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Leptospirosis by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Intravenous for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Leptospirosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Leptospirosis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Leptospirosis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Leptospirosis by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Leptospirosis by Diagnosis - Percentage Breakdown of Value Sales for Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis for the Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Leptospirosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Latin America 15-Year Perspective for Leptospirosis by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Intravenous for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for Leptospirosis by Diagnosis - Percentage Breakdown of Value Sales for Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis for the Years 2015, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Leptospirosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: Argentina 15-Year Perspective for Leptospirosis by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Intravenous for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for Leptospirosis by Diagnosis - Percentage Breakdown of Value Sales for Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis for the Years 2015, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Leptospirosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 226: Brazil 15-Year Perspective for Leptospirosis by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Intravenous for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for Leptospirosis by Diagnosis - Percentage Breakdown of Value Sales for Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis for the Years 2015, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Leptospirosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 235: Mexico 15-Year Perspective for Leptospirosis by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Intravenous for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for Leptospirosis by Diagnosis - Percentage Breakdown of Value Sales for Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Leptospirosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 15-Year Perspective for Leptospirosis by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Intravenous for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Leptospirosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Leptospirosis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Leptospirosis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Leptospirosis by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Leptospirosis by Diagnosis - Percentage Breakdown of Value Sales for Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis for the Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Leptospirosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 256: Middle East 15-Year Perspective for Leptospirosis by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Intravenous for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for Leptospirosis by Diagnosis - Percentage Breakdown of Value Sales for Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis for the Years 2015, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Leptospirosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 265: Iran 15-Year Perspective for Leptospirosis by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Intravenous for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for Leptospirosis by Diagnosis - Percentage Breakdown of Value Sales for Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis for the Years 2015, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Leptospirosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 274: Israel 15-Year Perspective for Leptospirosis by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Intravenous for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for Leptospirosis by Diagnosis - Percentage Breakdown of Value Sales for Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis for the Years 2015, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Leptospirosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 15-Year Perspective for Leptospirosis by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Intravenous for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for Leptospirosis by Diagnosis - Percentage Breakdown of Value Sales for Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis for the Years 2015, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Leptospirosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 292: UAE 15-Year Perspective for Leptospirosis by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Intravenous for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for Leptospirosis by Diagnosis - Percentage Breakdown of Value Sales for Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis for the Years 2015, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Leptospirosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 15-Year Perspective for Leptospirosis by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Intravenous for the Years 2015, 2025 & 2030
• AFRICA
  • Leptospirosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Leptospirosis by Diagnosis - Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for Leptospirosis by Diagnosis - Percentage Breakdown of Value Sales for Complete Blood Count, Creatine Kinase, Liver Enzymes, Urinalysis and Other Diagnosis for the Years 2015, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Leptospirosis by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Leptospirosis by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Leptospirosis by Administration Route - Oral, Parenteral and Intravenous Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 310: Africa 15-Year Perspective for Leptospirosis by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Intravenous for the Years 2015, 2025 & 2030

IV. COMPETITION